1,198 results on '"Drayson, Mark T"'
Search Results
2. Physical activity and sleep relate to antibody maintenance following naturalistic infection and/or vaccination in older adults
3. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
4. Saliva antiviral antibody levels are detectable but correlate poorly with serum antibody levels following SARS-CoV-2 infection and/or vaccination
5. Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
6. Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma
7. Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing
8. Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade
9. Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies
10. Brief cycling intervals incrementally increase the number of hematopoietic stem and progenitor cells in human peripheral blood.
11. Infectious Diseases
12. Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
13. Salivary free light chains as a new biomarker to measure psychological stress: the impact of a university exam period on salivary immunoglobulins, cortisol, DHEA and symptoms of infection
14. Free light chains as an emerging biomarker in saliva: Biological variability and comparisons with salivary IgA and steroid hormones
15. Sensitive Detection of SARS-CoV-2-Specific Antibodies in Dried Blood Spot Samples
16. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
17. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
18. Selective effects of acute low-grade inflammation on human visual attention
19. Loneliness in healthy young adults predicts inflammatory responsiveness to a mild immune challenge in vivo
20. Immunoglobulin free light chains: an inflammatory biomarker of diabetes
21. The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer
22. Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs
23. Low-grade inflammation decreases emotion recognition – Evidence from the vaccination model of inflammation
24. Inhibition ofNeisseria gonorrhoeaecomplement-mediated killing during acute gonorrhoea is dependent upon the IgG2:IgG3 antibody ratio
25. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma
26. Pathogen and human NDPK-proteins promote AML cell survival via monocyte NLRP3-inflammasome activation
27. Lymphocyte Migration in the Rat
28. Immunoglobulin Free Light Chains as Inflammatory Biomarkers of Atrial Fibrillation
29. Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management
30. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study
31. Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial
32. SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection
33. Abstract 5943: Plasma cell repertoire in the lung cancer tumor microenvironment
34. Clinical and laboratory characteristics of patients with symptomatic secondary immunodeficiency following the treatment of haematological malignancies
35. Plasma cell disorders supress mucosal anti-bacterial immunity: another dimension of immunoparesis in plasma cell neoplasms
36. Feasibility Of A Progressive Walking-based Exercise Programme In Clonal Plasma Cell Disorders: 4004 Board #321 May 30 9:00 AM - 10:30 AM
37. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
38. Supplementary material from The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma
39. Data from Nm23-H1 Indirectly Promotes the Survival of Acute Myeloid Leukemia Blast Cells by Binding to More Mature Components of the Leukemic Clone
40. Data from Drug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids
41. Supplementary Table S7: Mass spectrometry 13C-glucose tracer lipidomics data from Drug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids
42. Supplementary Figure S2: MSMS identification of lipids and polar compounds mentioned in the manuscript from Drug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids
43. Supplementary Table 1 from Nm23-H1 Indirectly Promotes the Survival of Acute Myeloid Leukemia Blast Cells by Binding to More Mature Components of the Leukemic Clone
44. Supplementary Table S6: Mass spectrometry lipidomics / metabolomics data from Drug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids
45. A repurposed drug combination (VaN) inhibits free light chain secretion and triggers the terminal unfolded protein response (UPR) in multiple myeloma (MM)
46. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
47. Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial
48. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
49. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations
50. Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.